In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay.
We have established a sensitive and specific radioreceptor assay for androgen receptor active materials in plasma, using tritiated methyltrienolone ([3H]R1881) as tracer, and spayed mouse kidney cytosol receptor as the binding species. On radioreceptor assay, plasma from mice chronically administered spironolactone contained approximately 10 times higher levels of androgen receptor active material than from mice administered potassium canrenoate. In parallel bioassays (antagonism of the effect of testosterone on seminal vesicle weight), spironolactone was greater than 4 times as potent an antiandrogen as potassium canrenoate. Administered potassium canrenoate circulates as canrenoic acid, in equilibrium with its lactonized congener canrenone. Since over 80% of administered spironolactone is irreversibly converted to canrenone/canrenoic acid, its much higher anti-androgen activity on radioreceptor assay and bioassay may point to the generation of unidentified, minor metabolites with very high affinity for androgen receptors and/or a very long plasma half-life.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002191:Canrenoic Acid / Q000494:pharmacology*; D003600:Cytosol / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D009919:Orchiectomy; D009929:Organ Size / Q000187:drug effects; D011245:Pregnadienes / Q000494:pharmacology*; D011944:Receptors, Androgen / Q000187:drug effects / Q000378:metabolism*; D012669:Seminal Vesicles / Q000187:drug effects; D013148:Spironolactone / Q000494:pharmacology*; D013739:Testosterone / Q000494:pharmacology
D011245:Pregnadienes; D011944:Receptors, Androgen; D013148:Spironolactone; D013739:Testosterone; D002191:Canrenoic Acid